Pub-2013

Articles

Title
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton's tyrosine kinase in Waldenstrom's macroglobulinemia
A new era for Waldenstrom macroglobulinemia: MYD88 L265P
MYD88 L265P in Waldenstrom's Macroglobulinemia, IgM Monoclonal Gammopathy, and other B-cell Lymphoproliferative Disorders using Conventional and Quantitative Allele-Specific PCR
Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration
Proceedings from the 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-7)
Proteasome inhibitors in Waldenström macroglobulinemia
Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
The Epidemiology of Herpes-Zoster in Patients with Newly Diagnosed Cancer
The genomic landscape of Waldenstrom's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like mutations, and small somatic deletions associated with B-cell lymphomagenesis.
Waldenstrom's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features